Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program

Background: Alemtuzumab is a humanized monoclonal antibody approved in several countries for treatment of relapsing-remitting multiple sclerosis (RRMS). This report summarizes the experience with infusion-associated reactions (IARs) in two phase 3 trials of alemtuzumab in RRMS and examines skilled n...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J MS Care
Egile Nagusiak: Caon, Christina, Namey, Marie, Meyer, Cathy, Mayer, Lori, Oyuela, Pedro, Margolin, David H., Rizzo, Marco
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The Consortium of Multiple Sclerosis Centers 2015
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542714/
https://ncbi.nlm.nih.gov/pubmed/26300705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2014-030
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak